Incorporating Novel Muscarinic Agents for Schizophrenia Into Clinical Practice: Overcoming Clinical Inertia
May 28, 2026
Miami Beach, Florida
07:00 AM - 08:00 AM ET
Redefining gMG Management: FcRn Antagonists and the New Era of Precision Neurology
September 30, 2026 Orlando, Florida
Turning Flares Into Function: Flag Uncontrolled Disease
Christyn Edmundson, MD
Gil I. Wolfe MD, FAAN
Minimal By Design: Define MSE Endpoints
When to Begin FcRn: Initiation Criteria, Key Evidence
Escalate With Intention: Stepwise, Target-Anchored Moves
The IgG Clock: Redose Using IgG Kinetics
APRIL Uncovered: An Upstream Driver in IgAN
Dana Rizk, MD
Hong Zhang
Translating Guidelines to Action in IgAN: Embracing a Simultaneous Dual-Concordant Approach
Richard Lafayette, MD, FACP
Suzuki Yusuke, MD, PhD
Inside the 4 Hits: Targeting APRIL to Change the Course of IgAN
Mechanism-Based Targeting: Why APRIL Matters in IgAN
Targeting Lower Proteinuria Levels: Shifting the Goalpost in IgAN
Beyond RAASi and Approved Therapies: The Unmet Needs in IgAN
Advancing Bispecific Antibodies Upstream in the Treatment Paradigm of Multiple Myeloma
María-Victoria Mateos, MD, PhD
From Late-Line Rescue to Early-Line Option: The Potential for Bispecific Antibodies in Multiple Myeloma
Luciano Costa, M.D., Ph.D.
Loading...
We're glad to see you're enjoying Prova Education… but how about a more personalized experience?
Press cancel to remain on Prova Education. Press the link below or the continue button to keep going.